Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

$94.13 Bn Controlled Release Drug Delivery Market Forecasts, 2025-2026 & 2031: Rising R&D Investments are Fueling Novel Technologies for Precise, Prolonged Release Profiles

globenewswire.com
MRK Merck & Co. is mentioned as a company developing and marketing pharmaceuticals with advanced delivery systems, including products like Keytruda and Januvia. The mention is in the context of the broader controlled release drug delivery market's growth drivers and key players, not specific to Merck's individual performance or outlook.

$94.13 Bn Controlled Release Drug Delivery Market Forecasts, 2025-2026 & 2031: Rising R&D Investments are Fueling Novel Technologies for Precise, Prolonged Release Profiles Dublin, April 28, 2026 (GLOBE NEWSWIRE) -- The "Controlled Release Drug Delivery Market - Forecast from 2026 to 2031" report has been added to ResearchAndMarkets.com's offering.

The Controlled Release Drug Delivery Market is forecasted to rise at a 9.74% CAGR, reaching USD 94.138 billion in 2031 from USD 53.902 billion in 2025.

The controlled release drug delivery market is advancing as systems ensure steady therapeutic levels, enhancing compliance in chronic disease management. Rising R&D investments are fueling novel technologies for precise, prolonged release profiles. Growth in generic production is delivering cost-effective controlled-release options. Aging populations are amplifying demand for safer, less frequent dosing regimens in long-term therapies.

Controlled release drug delivery systems maintain optimal API concentrations over extended periods, minimizing fluctuations and improving efficacy. These platforms reduce dosing frequency, boosting patient adherence and convenience while mitigating side effects from peak-trough variations. The market is expanding steadily, supported by chronic disease burden, regulatory encouragement, technological progress, and demographic shifts toward elderly cohorts requiring sustained treatments.

Key growth drivers include the inherent benefits of controlled release, such as sustained therapeutic levels, fewer administrations, and enhanced outcomes, particularly valuable for conditions demanding consistent management. Escalating chronic disease prevalence necessitates reliable, long-acting formulations to optimize control and reduce complications. Expansion of the generic segment enables broader access to affordable controlled-release equivalents of branded drugs, aligned with regulatory pathways ensuring bioequivalence and quality.

Heightened R&D expenditure, backed by institutional funding, accelerates innovations in delivery mechanisms like multi-particulates, matrix, and osmotic systems. The burgeoning aging population, with diminished physiological resilience and adherence challenges, favors low-frequency, tolerable dosing to support polypharmacy and quality of life.

Geographically, North America is projected for significant growth and share retention, attributed to elevated chronic disease rates, substantial healthcare spending, supportive regulations, geriatric demographics, and robust innovation ecosystem. The region's thriving generic industry further catalyzes controlled-release adoption.

Leading companies include Adare Pharma Solutions, a global CDMO specializing in oral dosage forms with controlled release via multi-particulates, matrix systems, osmotic platforms, and coated pellets for tailored, extended profiles. Colorcon excels in film coatings like Opadry to enhance durability, aesthetics, and release control in solid dosages. Merck & Co., Inc. develops and markets pharmaceuticals incorporating advanced delivery, exemplified by products like Keytruda (pembrolizumab), Januvia (sitagliptin), Gardasil (HPV vaccine), and ProQuad (measles/varicella vaccine).

Overall, the market is progressing robustly, positioned to address adherence barriers, therapeutic optimization, and accessibility amid chronic disease escalation and demographic transitions, with ongoing advancements in polymer, coating, and osmotic technologies broadening clinical utility.

Key Benefits of this Report:

Report Coverage:

Key Attributes:

Company Profiling (Strategies, Products, Financial Information, and Key Developments)

Controlled Release Drug Delivery Market Segmentation:

By Technology

By Release Mechanism

By Application

By Geography

For more information about this report visit https://www.researchandmarkets.com/r/y4h8n0

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment